相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
Weihua Li et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
Simon Strohmeier et al.
SCIENTIFIC REPORTS (2021)
Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Jessica Jiyeong Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR plus NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Hui Xia et al.
CLINICAL LUNG CANCER (2020)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2020)
Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC
Weihua Li et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.
Jianfei Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
Christian Diego Rolfo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer et al.
NEURO-ONCOLOGY (2020)
Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
R. McDermott et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
R. Dziadziuszko et al.
ANNALS OF ONCOLOGY (2020)
Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
T. John et al.
ANNALS OF ONCOLOGY (2020)
Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
A. Drilon et al.
ANNALS OF ONCOLOGY (2020)
A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
Anna Forsythe et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Noah Federman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
366PActivity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
D S Ziegler et al.
ANNALS OF ONCOLOGY (2019)
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Ryohei Katayama et al.
NATURE COMMUNICATIONS (2019)
PBI-200: A novel, brain penetrant, next generation pan-TRK kinase inhibitor
Anthony Regina et al.
CANCER RESEARCH (2019)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
G D Demetri et al.
ANNALS OF ONCOLOGY (2018)
409OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
U N Lassen et al.
ANNALS OF ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Non-small-cell lung cancer
Cesare Gridelli et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer
Rui Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain
Joseph R. Ghilardi et al.
MOLECULAR PAIN (2010)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
分享论文
